Chemical Patent Example
Enhanced Peptide Constructs for Albumin Binding
At a Glance
- Patent NumberUS 12,377,158
- IssuedAugust 5, 2025
- FiledJanuary 6, 2025
- InventorMichael Farber
- Claims5
About This Invention
Many therapeutic peptides and proteins clear from the body quickly, forcing frequent injections. This biotechnology patent protects engineered peptide constructs that bind therapeutic proteins to albumin — the most abundant protein in blood plasma, with a half-life of roughly 19 days — so the drug circulates far longer and can be administered less often. The claimed constructs bind human albumin with a dissociation constant below 20 nanomolar while preserving the biological activity of fused proteins such as Klotho.
Abstract
An albumin binding construct that enhances the pharmacokinetic performance of therapeutic peptides and proteins, extending their half-lives and reducing administration frequency, is disclosed. The core peptide DICLPRWGCLW (SEQ ID NO: 1) is covalently linked to hydrophilic, flexible glycine-serine (Gly-Ser) linkers of the formula (ggs)xgg where X is 3 to 8 units. These linkers provide strong albumin binding (dissociation constant <20 nanomolar). Some constructs feature the GGSGGSGGSGGRLIEDICLPRGCLWEDD (SEQ ID NO: 4) peptide and allow fusion of active proteins like Klotho, maintaining biological activity and leveraging albumin’s extended half-life. Constructs are produced using cellular expression systems (CHO, HEK293, Transgenic Insect Cells) for scalability. These constructs show prolonged half-lives comparable to at least 90% of native albumin. Klotho constructs using the albumin binder demonstrate FGF23 binding dissociation coefficients between 15-30 nanomolar, essentially the same as natural Klotho. Designed to minimize antigenicity, these constructs improve drug delivery efficacy and patient outcomes.
Representative Claim
Claim 1 of 5 — the complete claim set is available in the full patent record.
1. An albumin binding construct, comprising: an SA21 peptide comprising a core peptide DICLPRWGCLW (SEQ ID NO: 1) covalently attached to a c-terminus of a glycine-serine linker comprising a sequence of GGSGGSGGSGG (SEQ ID NO: 3);
said glycine-serine linker being hydrophilic and flexible, wherein the albumin binding constructs binds to human albumin with a binding dissociation constant value of less than 20 nanomolar to human albumin.
Have an invention like this?
Talk directly with a patent attorney about protecting your chemical and biotech invention. We handle the entire process — from the first consultation through issuance — and wherever possible we work on flat fees, so you know your cost up front.